DigestRedComo funciona
Red
/
Empresas
Co
No verificado

Corcept Therapeutics Incorporated

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

43 Comunicados de prensa

Ver todos los comunicados de prensa
06/06/2026
Ciencia
Salud
Medicina - Varios
Biotecnología
Farmacéutica
Sanidad
Oncología
Eventos
Ferias y Congresos
Industria
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
29/05/2026
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
27/05/2026
Industria
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
30/04/2026
Web y redes sociales
Telefonía
Mercado de valores
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
30/04/2026
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
23/04/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
21/04/2026
Eventos
Ferias y Congresos
Industria
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
10/04/2026
Eventos
Industria
Oncología
Salud
Ir de compras
Medicina - Varios
Farmacéutica
Biotecnología
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
28/03/2026
Eventos
Cardiología
Biotecnología
Farmacéutica
Sanidad
Oncología
Salud
Medicina - Varios
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0
25/03/2026
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
Fuente
Corcept Therapeutics Incorporated
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0